ENGLEWOOD, Colo., Sept. 26,
2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc.
(NYSE American: AMPE) (the "Company") a pre-revenue stage
biopharmaceutical Company focused on development of a potential
treatment for osteoarthritis as part of its OA.201 program, today
announced that its CEO, Michael A.
Martino will present in the Emerging Growth Conference on
Thursday, October 5, 2023 at
3:25 pm ET.
For investors who are interested in participating, please use
the link below to register and receive any conference updates:
Located in Englewood, Colorado,
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is focused on
development of a potential treatment for osteoarthritis as part of
its OA.201 program. The OA.201 development program is seeking
to advance Ampio's unique and proprietary small molecule
formulation to take forward through pain and chondroprotection
preclinical studies to the next phases of drug development to
address the large and attractive opportunity for treatment of
osteoarthritis of the knee (OAK) and other joints.
Caution Regarding Forward-Looking Statements
All statements other than statements of historical facts
contained in this letter, including statements regarding our
anticipated future clinical developments, future financial
position, and plans and objectives of management for future
operations, are forward-looking statements. Words such as "may",
"will", "should", "forecast", "could", "expect", "suggest",
"believe", "estimate", "continue", "anticipate", "intend",
"ongoing", "opportunity", "potential", "predicts", "seek", "plan,"
or similar words, or the negatives of such terms or other
variations on such terms or comparable terminology, typically
identify forward-looking statements.
Forward-looking statements are based on certain assumptions and
expectations of future events and trends that are subject to risks
and uncertainties including: we are dependent on the success of our
OA.201 program and we cannot be certain that any preclinical data
will support its further development; there can be no assurance
that we will be successful in identifying or completing any
strategic alternative or that any such strategic alternative will
yield value for our stockholders; we may not be able to manage
third parties to provide timely, high quality, and cost-effective
services to us; our history of losses and our cash resources
available to execute our business plan over the next twelve months
raise substantial doubt about our ability to continue as a going
concern; we are involved in legal proceedings that likely will
adversely affect our financial position and our pursuit of
strategic alternatives; we will need additional capital to fund our
future operations, the development of the OA.201 program and any
strategic transaction, as well as to assure compliance with the
NYSE American minimum stockholders' equity requirement; we are
dependent on adequate protection of our patent and proprietary
rights; the price of our stock has been and may continue to be
extremely volatile; if we cannot continue to satisfy the NYSE
American continued listing requirements and rules, our securities
may be delisted, which could negatively impact the price of our
securities; and other risks described in "Risk Factors" and
elsewhere in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 and
subsequent periodic reports filed with the SEC.
We undertake no obligation to update or revise publicly any
forward-looking statements to reflect events or circumstances after
the date of such statements for any reason, except as otherwise
required by law.
For more information, contact:
Ampio Pharmaceuticals, Inc.
Michael A. Martino
Chief Executive Officer
View original content to download
SOURCE Ampio Pharmaceuticals, Inc.